Objective-The purpose of this study was to determine the association between 25-hydroxyvitamin D (25(OH)D) levels and the prevalence of peripheral arterial disease (PAD) 4 Basic science research indicates that low vitamin D levels may be linked with cardiovascular risk. Vascular smooth muscle cells possess the 1-␣ hydroxylase enzyme that locally activates circulating vitamin D. 5 In animal models, active vitamin D is an inhibitor of the renin-angiotensin system 6 and myocardial cell hypertrophy. 7 Cellular experiments show that active vitamin D and its analogs exhibit anticoagulant activity. 8 Conflicting data are available on the association between low 25(OH)D levels and cardiovascular disease in the general population. 9 -11 Among adults, 25-hydroxyvitamin D (25(OH)D) levels Ն30 ng/mL are considered optimal. 12 These levels are associated with reduced fracture rates and have been postulated to be associated with better health outcomes. 12 The goal of the current study was to evaluate the association between serum 25(OH)D levels and the prevalence of PAD in the general population. To accomplish this goal, we analyzed data from a nationally representative sample of the United States adult population aged Ն40 years in NHANES 2001 to 2004. In addition, elevated serum calcium, phosphate, and intact parathyroid hormone (iPTH) levels have been associated with cardiovascular disease in the general population. 13, 14 Because these serum markers are associated with vitamin D levels, we assessed the association between these serum markers and PAD in a secondary analysis.
P eripheral arterial disease (PAD) affects approximately 5 million US adults, and it is associated with a high risk of morbidity and mortality from cardiovascular disease. 1, 2 Established risk factors for PAD include typical atherosclerosis risk factors such as dyslipidemia, diabetes mellitus, hypertension, smoking, and reduced kidney function. 2, 3 In addition, nontraditional cardiovascular risk factors such as elevated C-reactive protein (CRP) and fibrinogen have been associated with PAD. 4 Basic science research indicates that low vitamin D levels may be linked with cardiovascular risk. Vascular smooth muscle cells possess the 1-␣ hydroxylase enzyme that locally activates circulating vitamin D. 5 In animal models, active vitamin D is an inhibitor of the renin-angiotensin system 6 and myocardial cell hypertrophy. 7 Cellular experiments show that active vitamin D and its analogs exhibit anticoagulant activity. 8 Conflicting data are available on the association between low 25(OH)D levels and cardiovascular disease in the general population. 9 -11 Among adults, 25-hydroxyvitamin D (25(OH)D) levels Ն30 ng/mL are considered optimal. 12 These levels are associated with reduced fracture rates and have been postulated to be associated with better health outcomes. 12 The goal of the current study was to evaluate the association between serum 25(OH)D levels and the prevalence of PAD in the general population. To accomplish this goal, we analyzed data from a nationally representative sample of the United States adult population aged Ն40 years in NHANES 2001 to 2004. In addition, elevated serum calcium, phosphate, and intact parathyroid hormone (iPTH) levels have been associated with cardiovascular disease in the general population. 13, 14 Because these serum markers are associated with vitamin D levels, we assessed the association between these serum markers and PAD in a secondary analysis. 
Methods

Study Population
Study Variables
Study procedures in NHANES 2001 to 2004 consisted of an in-home interview followed by a medical evaluation and blood sample collection at a mobile examination center. Of relevance to the current analysis, variables collected during the in-home interview included age, gender, race-ethnicity, cigarette smoking, education, leisuretime physical activity, and a history of diabetes mellitus and myocardial infarction. For the current analysis, self-reported raceethnicity was categorized as non-Hispanic white, non-Hispanic black, Mexican-American, and other. Participants who reported having smoked Ն100 cigarettes during their lifetime were classified as current or former smokers if they answered affirmatively or negatively, respectively, to the question "Do you smoke cigarettes now?" Diabetes mellitus was defined as a self-report of a physician diagnosis, not during pregnancy, with concurrent use of oral hypoglycemic or insulin medication. A history of myocardial infarction was based on participants' self-report of a previous physician diagnosis on the medical history questionnaire. Being physically active was defined as participating in 30 or more minutes of moderate or vigorous activity or strength training in the 30 days preceding the NHANES visit.
The NHANES 2001 to 2004 examination procedures included measurement of height, weight, and blood pressure. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Normal weight, overweight, and obesity were defined as a BMI of Ͻ25 kg/m 2 , 25 to Ͻ30 kg/m 2 , and Ն30 kg/m 2 , respectively. Three blood pressure measurements were taken during a single examination visit by a physician using a protocol adapted from the American Heart Association. Based on the average of all 3 blood pressure measurements, hypertension was defined as systolic or diastolic blood pressure Ն140 mm Hg or 90 mm Hg, respectively, or self-reported current use of blood pressure lowering medication. Medication and supplement use data were obtained for use of statins, antihypertensives, antidiabetes medications, and vitamin D supplementation through questionnaires and pill bottle reviews.
Detailed descriptions of blood collection and processing procedures are provided in the NHANES Laboratory/Medical Technologists Procedures Manual. 15 Serum creatinine concentration was measured using the modified kinetic method of Jaffe, calibrated to the assays used for the development of the Modification of Diet in Renal Disease (MDRD) Study equation, and glomerular filtration rate was estimated with the simplified MDRD equation. 16 Participants with an estimated glomerular filtration rate of Ͻ60 mL/min/ 1.73 m 2 were considered to have chronic kidney disease (CKD). High-sensitivity CRP was measured by latex-enhanced nephelometry. Elevated CRP was defined as Ն1.0 mg/L. Total plasma homocysteine levels were measured by the Abbott Homocysteine assay. Total and HDL-cholesterol, serum calcium, and phosphate levels were measured on the Beckman Synchron LX20. Serum calcium was corrected for serum albumin using the formula: adjusted calciumϭmeasured calciumϪ [(4.0Ϫserum 
Outcome
The primary outcome for the current study was PAD defined using ABI. Details of the methods used to measure ABI in NHANES have been described previously. 17 In brief, for participants with at least 1 arm and weighing Յ400 pounds, systolic blood pressure for the ABI was measured via blood pressure cuffs on the right brachial artery and both posterior tibial arteries. For participants aged 40 to 59 years, 2 measures were taken and averaged at each site, whereas for participants aged Ն60 years, 1 measure was taken. For individuals with conditions precluding measurement of the right arm, left brachial artery systolic blood pressure was taken. ABI was calculated as the ratio of the average ankle systolic blood pressure to arm systolic blood pressure. The smaller of the 2 measurements was considered the ABI for this study. Participants with ABI Ն1.5 may have severe arterial rigidity and were therefore excluded from all analyses (nϭ10). PAD was defined as ABI Ͻ0.9.
Statistical Analysis
Participant characteristics were calculated by PAD status. The statistical significance of differences for these characteristics was determined using least squares and maximum likelihood for continuous and dichotomous variables, respectively. Next, the prevalence of PAD was calculated by quartile of 25(OH)D, with the statistical significance of trends across quartile assessed using maximum likelihood. Prevalence ratios of PAD associated with quartile of serum 25(OH)D were calculated using log binomial regression models. An initial model included adjustment for age, gender, and race-ethnicity with a subsequent model including additional adjustment for education, current and former cigarette smoking, leisuretime physical activity, diabetes mellitus, total to HDL cholesterol ratio, body mass index, systolic blood pressure, log homocysteine, glycohemoglobin, statin use, antihypertensive medication use, vitamin D supplement use, history of myocardial infarction, elevated CRP, and chronic kidney disease. To further explore the doseresponse relationship of 25(OH)D with PAD, we used restricted quadratic splines with knots at the 10th, 50th, and 90th percentiles of the 25(OH)D distribution (12.4, 23.4, 34.3 ng/mL, respectively). The multivariable-adjusted association between 25(OH)D, as continuous variable, and PAD was determined overall and for subgroups defined by age, gender, race-ethnicity, BMI, physical activity, diabetes mellitus, a history of myocardial infarction, chronic kidney disease, and vitamin D supplement use. For analyses as a continuous variable, the prevalence ratio of PAD was calculated for 1 standard deviation lower serum 25(OH)D (10 ng/mL). Differences in the association of 25(OH)D and PAD across subgroup were tested by using a multiplicative term in the regression models. Additionally, the associations between serum calcium, phosphate, and iPTH, each modeled by quartile and as continuous variables, and PAD were determined. Data were analyzed using SUDAAN (version 9.0; Research Triangle Institute) to account for the complex NHANES sampling design including unequal probabilities of selection, oversampling, and nonresponse.
Results
Participant Characteristics
Participants with PAD were older, more likely to be nonHispanic black, have less than a high school education, be a former smoker, and have diabetes mellitus, higher glycohemoglobin levels, hypertension, a history of myocardial infarction, chronic kidney disease, use statins, and have elevated homocysteine and CRP (Table 1) . Additionally, those with PAD were less likely to be physically active. There was no difference in serum calcium, phosphate, or iPTH levels between participants with and without PAD. In contrast, mean 25(OH)D levels were significantly lower among participants with PAD (PϽ0.001).
Associations Between Serum 25 (OH) Vitamin D Levels and PAD
A graded association was present between lower 25(OH)D levels and a higher prevalence of PAD ( 
Subgroup Analysis
After multivariable adjustment, the prevalence ratio of PAD associated with each 10 ng/mL lower 25(OH)D was 1.35 (95% CI: 1.15, 1.59; Figure 2 ). The association between 25(OH)D and PAD was similar (probability value for interaction Ͼ0.10) in all subgroups except physical activity. Specifically, the prevalence ratio of PAD per each 10 ng/mL lower 25(OH)D was 1.61 (95% CI: 1.19, 2.18) and 1.13 (95% CI: 0.95, 1.35) for those who were and were not physically active, respectively (P interactionϭ0.06).
Associations of Serum Calcium, Phosphate, and iPTH Levels and PAD
Higher quartiles of serum calcium, phosphate, and iPTH levels were not associated with PAD (Table 3) . Additionally, modeled as a continuous variable, there was no association between serum calcium, phosphate, or iPTH and PAD, overall, or in subgroups (data not shown).
Discussion
In this nationally representative sample of US adults, there was a strong, graded association between lower levels of 25(OH)D levels and PAD. This association was present after adjustment for several cardiovascular risk factors and potential confounders. In contrast, no association was present between elevated serum calcium, phosphate or iPTH levels, and PAD in this population. PAD is defined as an ankle brachial index Ͻ0.9. †Values are median (25th to 75th percentiles).
Melamed et al Vitamin D and PAD
Epidemiological studies have shown an inverse association between blood pressure and vitamin D levels 18 and a direct association between increasing latitude, as a surrogate of lower vitamin D levels, and blood pressure. 19 One small clinical trial suggested that oral vitamin D supplementation 20 reduces systolic blood pressure. Additionally, in another trial, patients randomized to ultraviolet light exposure 3 times a week experienced a 180% increase in 25(OH)D levels and improved blood pressure control. 21 However, another small study did not show this effect on blood pressure. 22 The association of 25(OH)D deficiency with glucose intolerance 23 and the metabolic syndrome 24 is another potential mechanism for increased cardiovascular disease risk. In 1 study of older adults with impaired fasting glucose, supplementation with vitamin D and calcium attenuated the progression of insulin resistance and hyperglycemia. 25 However, in the current study, a graded association between 25(OH)D and PAD remained present after adjustment for diabetes mellitus and glycohemoglobin.
The association of both 25(OH)D and 1,25(OH) 2 vitamin D levels with cardiovascular events remains controversial. In some studies, low 25(OH)D levels have been associated with increased prevalence of coronary heart disease (CHD), 9 stroke, 26 and congestive heart failure. 27 However, low 25(OH)D has been associated with a protective association in other studies. For example, in a case-control study of 143 patients with CHD by Rajasree, 25(OH)D levels Ͼ89 ng/mL were associated with a multivariable-adjusted odds ratio for CHD of 3.18 (95% CI: 1.31, 7.73). 10 In contrast, in a case-control study of acute myocardial infarction by Scragg, 25(OH)D levels above the median (Ն12.8 ng/mL) were protective against CHD (multivariable adjusted odds ratioϭ0.43, 95% CI: 0.27, 0.69). 9 In the Scragg study, 25(OH)D levels were notably lower than in the study by Rajasree. 10 Among 1739 Framingham Offspring Study participants free of cardiovascular disease at baseline, a 25(OH)D level Ͻ15 ng/mL was associated with a multivariable-adjusted 62% higher hazard of developing a first cardiovascular event. 11 Interestingly, PAD, defined as the onset of new claudication, was included in the outcome definition. However, PAD only comprised 8 of the 120 events in the study.
There are several lines of evidence suggesting that vitamin D may play a role in the pathogenesis of cardiovascular disease. Cardiac myocytes possess vitamin D receptors. 28 Several in vitro studies have shown that active vitamin D inhibits cardiac myocyte hypertrophy. 7, 29 Paricalcitol, an active vitamin D compound, attenuated the development of left ventricular hypertrophy in Dahl salt-sensitive rats. 30 Vitamin D has been shown to be an inhibitor of the reninangiotensin system. 6 In addition, several small studies have shown that supplementation with various forms of vitamin D may improve the cytokine profile (CRP, TNF-␣ levels) of patients with vitamin D deficiency 31 and congestive heart failure. 32 Cellular experiments showed that active vitamin D and its analogs exhibit anticoagulant activity. 8 Finally, the vitamin D-24-hydroxylase transgenic rat, a model of vitamin D deficiency attributable to continuous degradation of active vitamin D, develops aortic atherosclerosis. 33 Interestingly, an early experimental model of atherosclerosis was the cholesterol and vitamin D-fed rat. These rats were given an extremely high dose of vitamin D2 (1.8 million units/kg), and developed aortic atherosclerosis. 34 It is interesting that animal models of both excessive and insufficient vitamin D develop atherosclerosis and that there is conflicting human data on very high levels and very low levels of 25(OH)D being associated with cardiovascular disease 9 -11 suggesting that there may be an optimal level that is neither too high nor too low.
The results of the current study show that the association between low 25(OH)D levels and the prevalence of PAD was consistent across multiple subgroups. In the subgroup analyses, the association was stronger for non-Hispanic whites and for participants without diabetes mellitus. However, the interaction terms were not significant for non-Hispanic blacks versus whites (P interactionϭ0.31) or diabetes status (P interactionϭ0.19). Although one should be cautious interpreting the results from subgroup analyses because of the reduced sample size and statistical power, these results are similar to those reported by Scragg et al. 35 This line of investigation deserves further research.
The association we report is cross-sectional, similar to 2 previous smaller studies of 25(OH)D and PAD. 36, 37 In a study of 161 patients with angiographically proven PAD, those with Stage II PAD, defined as the presence of claudication symptoms, had higher mean 25(OH)D levels (23.4 ng/mL) compared to patients with Stage IV PAD, defined as the presence of ulcers (9.4 ng/mL). 37 Similarly, in a separate study of 95 patients with angiographically proven PAD, patients with Stage II PAD had higher 25(OH)D levels compared to Stage IV PAD. 36 The results of the current study extend these findings to a large nationally representative population with clinical and subclinical PAD.
High iPTH levels have been associated with cardiovascular disease in the general population. 13 Elevated serum phosphate levels have also been associated with cardiovascular events, a composite outcome which included peripheral vascular disease, in a community-based study. 14 Despite these suggestive findings, we did not find an association between serum calcium, phosphate, and iPTH levels and the prevalence of PAD. There are potential limitations to the current study. Most notably, the study was cross-sectional. As in any crosssectional study, one must be cautious in interpreting the direction of the association. It has been hypothesized that patients with PAD may be less mobile and therefore receive less sun exposure and have lower 25(OH)D levels. Although this may be the case for severe PAD, all participants in the current study were noninstitutionalized and mobile enough to attend the NHANES visit. An additional limitation is the lack of data in NHANES on sun exposure, geographic location, and the season during which participants attended their study visits. Another potential limitation is that angiography was not used to detect PAD, which was impractical in a large, population-based survey. Despite these limitations, the current study maintains several strengths. Using the ABI allowed us to identify the presence of subclinical PAD. NHANES included a broad range of data collection. This allowed us to study 25(OH)D, calcium, phosphate, and iPTH and perform statistical analyses after adjustment for several potential confounding factors. Additional strengths include standardized protocols with rigorous quality control for data collection and inclusion of a large nationally representative study sample. The large sample size allowed the investigation of the association between 25(OH)D and PAD in several important subgroups. The consistency of the results in these subgroups is noteworthy.
In summary, in this nationally representative study, US adults with low 25(OH)D levels had a higher prevalence of PAD. This association was strong, graded, and present after adjustment for multiple cardiovascular risk factors. Prospective and mechanistic studies are needed to confirm these associations.
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